ethyl(phenyl)zinc (313374-39-9) intermediate

Application context (from source-drug indications)

Lower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin SuccinateUrge incontinenceSolifenacin SuccinateUrinary tract diseaseSolifenacin Succinate

Source drugs (routes using this intermediate)

Drug	Tier	Expiry
Solifenacin Succinate/Tamsulosin Hydrochloride	Tier C — Watch / trade	-
Solifenacin Succinate	Tier B — Position early	-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Solifenacin Succinate/Tamsulosin HydrochlorideOptimised routesteps: 5total yield: 142.8 mg

(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline→(R)-quinuclidin-3-ol→4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane→ethyl(phenyl)zinc→3,4-dihydroisoquinoline 2-oxide→tert-butyl ((2S,3S)-3-methyl-1-morpholinopentan-2-yl)carbamate→(S)-1-phenyl-3,4-dihydroisoquinolin-2(1H)-ol→4-nitrophenyl carbonochloridate→4-nitrophenyl (S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate

Solifenacin SuccinateOptimised routesteps: 5total yield: 142.8 mg

(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline→(R)-quinuclidin-3-ol→4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane→ethyl(phenyl)zinc→3,4-dihydroisoquinoline 2-oxide→tert-butyl ((2S,3S)-3-methyl-1-morpholinopentan-2-yl)carbamate→(S)-1-phenyl-3,4-dihydroisoquinolin-2(1H)-ol→4-nitrophenyl carbonochloridate→4-nitrophenyl (S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.